Related references
Note: Only part of the references are listed.Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial
Waleed Ghanima et al.
LANCET (2015)
Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity
Guillaume Moulis et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Profound symptomatic hypogammaglobulinemia: A rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature.
Romain Levy et al.
AUTOIMMUNITY REVIEWS (2014)
Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients
Mehdi Khellaf et al.
BLOOD (2014)
Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up
Sigurdur Y. Kristinsson et al.
HAEMATOLOGICA (2014)
Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia
Matthieu Mahevas et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia
Sif Gudbrandsdottir et al.
BLOOD (2013)
The effect of rituximab on vaccine responses in patients with immune thrombocytopenia
Ishac Nazi et al.
BLOOD (2013)
Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia
Francesco Zaja et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia
Donald M. Arnold et al.
BLOOD (2012)
How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment
Waleed Ghanima et al.
BLOOD (2012)
Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia
Vivek L. Patel et al.
BLOOD (2012)
Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis
Sophie Auger et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Late-Onset Neutropenia Following Rituximab Therapy in Rheumatic Diseases: Association With B Lymphocyte Depletion and Infections
Daniel Tesfa et al.
ARTHRITIS AND RHEUMATISM (2011)
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
Cindy Neunert et al.
BLOOD (2011)
International consensus report on the investigation and management of primary immune thrombocytopenia
Drew Provan et al.
BLOOD (2010)
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia
Francesco Zaja et al.
BLOOD (2010)
Does rituximab aggravate pre-existing hypogammaglobulinaemia?
Lavanya Diwakar et al.
JOURNAL OF CLINICAL PATHOLOGY (2010)
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
Francesco Rodeghiero et al.
BLOOD (2009)
Rituximab efficacy and. safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura:: results of a prospective multicenter phase 2 study
Bertrand Godeau et al.
BLOOD (2008)
Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias
Aarati Rao et al.
PEDIATRIC BLOOD & CANCER (2008)
Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults
Drew Provan et al.
HAEMATOLOGICA (2007)
Systematic review: Efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura
Donald M. Arnold et al.
ANNALS OF INTERNAL MEDICINE (2007)
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia
F Zaja et al.
EXPERIMENTAL HEMATOLOGY (2006)
The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura
N Cooper et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Share Paper
